Interleukin-6: A Potential Biomarker of Resistance to Multitargeted Receptor Tyrosine Kinase Inhibitors in Castration-resistant Prostate Cancer
- 31 October 2011
- journal article
- Published by Elsevier BV in Urology
- Vol. 78 (4), 968.e7-968.e11
- https://doi.org/10.1016/j.urology.2011.07.1384
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine arrayBritish Journal of Cancer, 2009
- Immunotherapy for Prostate Cancer: Walk, Don't RunJournal of Clinical Oncology, 2009
- Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cellsLeukemia, 2009
- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapyAnnals of Oncology, 2009
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II StudyJournal of Clinical Oncology, 2009
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerThe New England Journal of Medicine, 2004
- Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancerBritish Journal of Cancer, 2004
- Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancerProstate Cancer and Prostatic Diseases, 2001
- Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.1998